1900 Wealth Management LLC Increases Holdings in Eli Lilly and Company $LLY

1900 Wealth Management LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 117.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,098 shares of the company’s stock after buying an additional 592 shares during the quarter. 1900 Wealth Management LLC’s holdings in Eli Lilly and Company were worth $838,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Lazard Freres Gestion S.A.S. raised its position in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC grew its position in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Central Pacific Bank Trust Division increased its stake in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $54,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.1%

NYSE:LLY opened at $1,079.84 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The business has a fifty day moving average price of $997.74 and a 200-day moving average price of $845.33. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.83, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Guggenheim reissued a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Leerink Partners restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.